Vaccines

Dr Muller and Dr Offit discuss recent developments in the COVID-19 vaccine for children younger than 5 years.

Dr Muller and Dr Offit discuss COVID-19 variants and their effect on vaccine development.

Move comes after FDA give emergency use authorization for bivalent vaccines.

In a recent study, investigators found lower rates of COVID-19 infection and other adverse outcomes in vaccinated pregnant people over those unvaccinated.

Latest emergency use authorizations for Moderna, Pfizer-BioNTech vaccines.

Paul A. Offit, MD, comments on spread of the COVID-19 virus in children who are vaccinated.

Vaccine and infectious disease experts address vaccine hesitancy and the importance of the COVID-19 vaccine in children.

William J. Muller, MD, PhD; and Paul A. Offit, MD, discuss the impact of COVID-19 on children.

Drs William J. Muller and Paul A. Offit discuss differences in response to vaccines in children compared to adults.

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

Only one-fifth of parents in a recent survey indicated intentions of getting their child the vaccine within 3 months of eligibility.

Learn about the selected strains for this year’s flu season, flu vaccine recommendation changes, and newly licensed and forthcoming vaccine options.

As immunization rates fall in children, the American Academy of Pediatrics recommends a checkup with physicians.

Purchase follows FDA recommendation to include Omicron component in boosters.

In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.

Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.

Recently, the AAP announced the launch of a public health campaign to educate caregivers on the benefits of vaccinating all ages.

The FDA today approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.

The FDA today announces the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.

In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.

GSK plc today announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

What we can look forward to in preventing infectious diseases.

Rochelle Walensky, MD endorsed the recommendation from the members of the CDC's Advisory Committee on Immunization Practices to administer Pfizer/BioNTech's COVID-19 vaccine for children aged 5-11 years.

The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.

The US Food and Drug Administration (FDA) committee voted on whether the emergency use authorization should be extended to children aged 5 to 11 years.

The US Food and Drug Administration (FDA) is meeting to discuss amending the emergency use authorization of the Pfizer/BioNTech vaccine for children aged 5 to 11 years.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.

Initial results from the trial indicate it was well-tolerated and promoted a good immune response.

Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Disease, reveals when he believes a COVID-19 vaccine for children aged less than 12 years will be available.